Sept 11 (Reuters) - XBRANE BIOPHARMA AB ::REG-XBRANE CONFIRMS ORDER OF SPHEROTIDE TO VALUE OF SEK 8.5 MILLION AND MORE THAN 10,000 DOSES SOLD.CONFIRMS ADDITIONAL ORDER OF SPHEROTIDE FROM POOYESH DAROU TO A VALUE OF SEK 8.5 MILLION TO BE DELIVERED IN Q4 2017.
Sept 8 (Reuters) - Horizon Discovery Group Plc ::ON TRACK TO MEET REVENUE GUIDANCE FOR ENLARGED GROUP OF 37-41 MILLION STG FOR FY2017, WITH STRONG H2 ORDER BOOK.GROUP EXPECTS TO REPORT SIX MONTH REVENUES OF 12.1 MILLION STG, IN LINE WITH PREVIOUS GUIDANCE,.GROUP EXPECTS TO REPORT NEGATIVE EBITDA IN H1 2017 IN LINE WITH ITS HISTORICAL H1:H2 PHASING OF REVENUE.GROUP IS ON TRACK TO ACHIEVE FY2017 REVENUE IN 30 MILLION STG- 33 MILLION STG RANGE ON AN ORGANIC BASIS.
Sept 1 (Reuters) - Dynavax Technologies Corp :Dynavax Technologies Corp says on August 21 court entered an order preliminarily approving a proposed settlement.Dynavax Technologies - proposed settlement does not involve stockholder class actions consolidated under caption in re Dynavax securities litigation.Dynavax Technologies Corp - litigation is currently pending in United States district court, northern district of California.
Aug 28 (Reuters) - Five Prime Therapeutics Inc :Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201').On august 28, 2017, Fiveprime delivered to Inhibrx written notice of termination of agreement for convenience.
Aug 18 (Reuters) - Celltrion Inc <068270.KQ> ::* Says it signed a 56.96 billion won contract with Celltrion Healthcare Co., Ltd to provide biosimilar antibody drug.
Aug 15 (Reuters) - Bellicum Pharmaceuticals Inc ::Bellicum Pharmaceuticals says on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas .Bellicum Pharmaceuticals- under agreement CPRIT awarded grant of about $16.9 million to bellicum to fund research of a cancer therapy involving BPX-501.Bellicum Pharmaceuticals Inc - Bellicum and CPRIT will retain joint ownership over any intellectual property developed under agreement.Bellicum Pharmaceuticals Inc - agreement will expire on February 29, 2020.
Aug 15 (Reuters) - DIAMYD MEDICAL AB :DIAMYD MEDICAL ORDERS ADDITIONAL DIAMYD® DRUG SUBSTANCE FROM PROTEIN SCIENCES.ORDER TOTALS APPROXIMATELY USD 750,000 (APPROXIMATELY MSEK 6.1).
Aug 11(Reuters) - Chengzhi Shareholding Co Ltd <000990.SZ>:Says its Nanjing-based clean energy unit will receive compensation of 141.7 million yuan from Nanjing-based firm CNAIC before Aug. 14, regarding hydrogen supply contract termination.Previous news was disclosed on May 15.